CD68 and cancer: Therefore, this study’s findings and the mounting conflicting evidence between different cancers, indicates that CD68+ TAMs may be a poor prognostic biomarker in OSCC or at least requires further investigation across a variety of cancers/tumours as well as their TMEs.